Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for AZN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for AZN and 80,000+ other tickers.
See exactly how AZN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AZN and 80,000+ other tickers.
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with…
AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. AZN targets $80bn in revenues by 2030, supported by 14 current blockbusters and a pipeline potentially adding 12 more by the decade's end. Recent pipeline wins in oncology, respiratory, and immunology offset the eplontersen ATTR-CM study failure and Farxiga's US LOE.
The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc's (NYSE:AZN) Ultomiris (ravulizumab) to lower proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.
AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.1 The US Food and Drug Administration granted accelerated approval to ZEGFROVY based on res.
AstraZeneca says FDA approves drug for rare kidney disease in adults